How Much Do You Want Your Doctors To Say About Risks of Treatment?

This kind of paternalism, when a doctor assesses the risks and benefits, and spares the patient’s “knowing” seems anachronistic. But it may, still, be what many people are looking for when and if they get a serious illness. Not everyone wants a “tell me everything” kind of physician.

EMILIA Trial: T-DM1 Appears Helpful in Women with Her2+ Metastatic Breast Cancer

The new agent is a hybrid of an old monoclonal antibody, Herceptin, that’s chemically attached to DM1, a traditional kind of chemotherapy. The preliminary results of this randomized trial are encouraging. …It’s hard to know how this promising, likely expensive, intravenous drug will fit in with others for patients with Her2+ breast cancer.

newsletter software